Status:
UNKNOWN
Characteristics of Blood Glucose Variability in Patients With Type 2 Diabetes Mellitus and COVID-19
Lead Sponsor:
Qilu Hospital of Shandong University
Conditions:
COVID-19 Pneumonia
Type2diabetes
Eligibility:
All Genders
18-100 years
Brief Summary
using intermittently scanned continuous glucose monitoring (isCGM) to clarify the characteristics of blood glucose variability parameters in T2DM patients with NCP, guide the formulation of reasonable...
Detailed Description
patients with NCP who were discharged or died. Clinical data and blood glucose variability parameters were collected by computer blood glucose monitoring technology (CGM). Time in range (TIR), time ab...
Eligibility Criteria
Inclusion
- All patients met the diagnostic criteria of type 2 diabetes mellitus in "Chinese Guidelines for the Prevention and treatment of type 2 Diabetes Mellitus (2020 edition)" formulated by the Chinese Diabetes Society of the Chinese Medical Association, and were previously diagnosed with type 2 diabetes mellitus and newly diagnosed with type 2 diabetes mellitus after admission
- Patients with mild, moderate, severe and critical COVID-19 in accordance with the guidelines of "Diagnosis and Treatment of novel coronavirus Infection (Trial version 10)"
- Patients receiving CGM or peripheral blood glucose monitoring during hospitalization
Exclusion
- Cases with incomplete data
- Non-NCP and non-T2DM patients
- Patients who did not receive CGM or peripheral blood glucose monitoring
Key Trial Info
Start Date :
August 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 1 2024
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT06156137
Start Date
August 1 2023
End Date
August 1 2024
Last Update
December 5 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Qilu hospital of shandong university
Jinan, Shandong, China, 250012